Monopar Therapeutics Inc. (MNPR) Misses Q4 EPS by 1c

Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q4 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Deutsche Bank Starts DexCom (DXCM) at Buy
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits